The potential role of vitamin D binding protein in kidney disease: a comprehensive review

Joris R Delanghe1, Charlotte Delrue2, Reinhart Speeckaert3

  • 1Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.

Acta Clinica Belgica
|January 3, 2024
PubMed

Insights

Vitamin D binding protein (VDBP) plays a key role in chronic kidney disease (CKD) by influencing bone health and inflammation. Understanding VDBP may lead to better CKD diagnostics and personalized treatments.

Area of Science:

  • Nephrology
  • Endocrinology
  • Immunology

Background:

  • Chronic kidney disease (CKD) is a significant global health issue.
  • Vitamin D binding protein (VDBP) is crucial for vitamin D metabolism and immune function.
  • VDBP's role in CKD pathogenesis is increasingly recognized.

Purpose of the Study:

  • To review the multifaceted roles of VDBP in the context of CKD.
  • To explore VDBP's impact on bone mineral homeostasis and inflammation in CKD.
  • To examine VDBP's potential as a diagnostic biomarker and therapeutic target for CKD.

Main Methods:

  • Literature review focusing on VDBP's molecular dynamics and interactions.
  • Analysis of VDBP's influence on calcium and phosphorus metabolism.
  • Examination of VDBP's immunomodulatory effects and genetic polymorphisms in CKD.

Main Results:

  • VDBP significantly impacts bone mineral homeostasis and CKD pathophysiology.
  • VDBP exhibits immunomodulatory properties that may mitigate CKD-related inflammation.
  • VDBP shows promise as a biomarker for early CKD detection and prognosis.

Conclusions:

  • VDBP is a critical factor in CKD, affecting mineral metabolism and immune responses.
  • Targeting VDBP offers potential for novel diagnostic and therapeutic strategies in CKD.
  • Further research into VDBP-CKD mechanisms and VDBP-targeted therapies is warranted.

Related Concept Videos

Role of Vitamins in Maintaining Bone Health01:25

Role of Vitamins in Maintaining Bone Health

The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...